391 related articles for article (PubMed ID: 38694508)
1. Antitumor activity of genetically engineered NK-cells in non-hematological solid tumor: a comprehensive review.
Dash CP; Sonowal D; Dhaka P; Yadav R; Chettri D; Satapathy BP; Sheoran P; Uttam V; Jain M; Jain A
Front Immunol; 2024; 15():1390498. PubMed ID: 38694508
[TBL] [Abstract][Full Text] [Related]
2. CAR-NK Cells: From Natural Basis to Design for Kill.
Khawar MB; Sun H
Front Immunol; 2021; 12():707542. PubMed ID: 34970253
[TBL] [Abstract][Full Text] [Related]
3. Natural killer cells in clinical development as non-engineered, engineered, and combination therapies.
Lamers-Kok N; Panella D; Georgoudaki AM; Liu H; Özkazanc D; Kučerová L; Duru AD; Spanholtz J; Raimo M
J Hematol Oncol; 2022 Nov; 15(1):164. PubMed ID: 36348457
[TBL] [Abstract][Full Text] [Related]
4. CAR-NK cells: A promising cellular immunotherapy for cancer.
Xie G; Dong H; Liang Y; Ham JD; Rizwan R; Chen J
EBioMedicine; 2020 Sep; 59():102975. PubMed ID: 32853984
[TBL] [Abstract][Full Text] [Related]
5. Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy.
Yilmaz A; Cui H; Caligiuri MA; Yu J
J Hematol Oncol; 2020 Dec; 13(1):168. PubMed ID: 33287875
[TBL] [Abstract][Full Text] [Related]
6. Engineering the Bridge between Innate and Adaptive Immunity for Cancer Immunotherapy: Focus on γδ T and NK Cells.
Morandi F; Yazdanifar M; Cocco C; Bertaina A; Airoldi I
Cells; 2020 Jul; 9(8):. PubMed ID: 32707982
[TBL] [Abstract][Full Text] [Related]
7. [Allogeneic CAR-NK cells: A promising alternative to autologous CAR-T cells - State of the art, sources of NK cells, limits and perspectives].
Nguyen S; Lacan C; Roos-Weil D
Bull Cancer; 2021 Oct; 108(10S):S81-S91. PubMed ID: 34920811
[TBL] [Abstract][Full Text] [Related]
8. Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity.
Rafei H; Daher M; Rezvani K
Br J Haematol; 2021 Apr; 193(2):216-230. PubMed ID: 33216984
[TBL] [Abstract][Full Text] [Related]
9. Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer.
Mehta RS; Rezvani K
Front Immunol; 2018; 9():283. PubMed ID: 29497427
[TBL] [Abstract][Full Text] [Related]
10. CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies.
Marofi F; Saleh MM; Rahman HS; Suksatan W; Al-Gazally ME; Abdelbasset WK; Thangavelu L; Yumashev AV; Hassanzadeh A; Yazdanifar M; Motavalli R; Pathak Y; Naimi A; Baradaran B; Nikoo M; Khiavi FM
Stem Cell Res Ther; 2021 Jul; 12(1):374. PubMed ID: 34215336
[TBL] [Abstract][Full Text] [Related]
11. Engineering Natural Killer Cells for Cancer Immunotherapy.
Rezvani K; Rouce R; Liu E; Shpall E
Mol Ther; 2017 Aug; 25(8):1769-1781. PubMed ID: 28668320
[TBL] [Abstract][Full Text] [Related]
12. Chimeric antigen receptor-natural killer cell therapy: current advancements and strategies to overcome challenges.
Kong JC; Sa'ad MA; Vijayan HM; Ravichandran M; Balakrishnan V; Tham SK; Tye GJ
Front Immunol; 2024; 15():1384039. PubMed ID: 38726000
[TBL] [Abstract][Full Text] [Related]
13. CAR-NK cell in cancer immunotherapy; A promising frontier.
Marofi F; Abdul-Rasheed OF; Rahman HS; Budi HS; Jalil AT; Yumashev AV; Hassanzadeh A; Yazdanifar M; Motavalli R; Chartrand MS; Ahmadi M; Cid-Arreguid A; Jarahian M
Cancer Sci; 2021 Sep; 112(9):3427-3436. PubMed ID: 34050690
[TBL] [Abstract][Full Text] [Related]
14. Genetic Engineering of Natural Killer Cells for Enhanced Antitumor Function.
Mantesso S; Geerts D; Spanholtz J; Kučerová L
Front Immunol; 2020; 11():607131. PubMed ID: 33391277
[TBL] [Abstract][Full Text] [Related]
15. Purinergic targeting enhances immunotherapy of CD73
Wang J; Lupo KB; Chambers AM; Matosevic S
J Immunother Cancer; 2018 Dec; 6(1):136. PubMed ID: 30514403
[TBL] [Abstract][Full Text] [Related]
16. CAR-NK for tumor immunotherapy: Clinical transformation and future prospects.
Wang W; Jiang J; Wu C
Cancer Lett; 2020 Mar; 472():175-180. PubMed ID: 31790761
[TBL] [Abstract][Full Text] [Related]
17. Engineering the next generation of CAR-NK immunotherapies.
Biederstädt A; Rezvani K
Int J Hematol; 2021 Nov; 114(5):554-571. PubMed ID: 34453686
[TBL] [Abstract][Full Text] [Related]
18. Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell.
Lin C; Zhang J
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):200-215. PubMed ID: 29378229
[TBL] [Abstract][Full Text] [Related]
19. Chimeric antigen receptor- and natural killer cell receptor-engineered innate killer cells in cancer immunotherapy.
Zhang C; Hu Y; Xiao W; Tian Z
Cell Mol Immunol; 2021 Sep; 18(9):2083-2100. PubMed ID: 34267335
[TBL] [Abstract][Full Text] [Related]
20. Genetically engineered CAR NK cells display selective cytotoxicity against FLT3-positive B-ALL and inhibit in vivo leukemia growth.
Oelsner S; Waldmann A; Billmeier A; Röder J; Lindner A; Ullrich E; Marschalek R; Dotti G; Jung G; Große-Hovest L; Oberoi P; Bader P; Wels WS
Int J Cancer; 2019 Oct; 145(7):1935-1945. PubMed ID: 30860598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
